Scalp cooling for the prevention of chemotherapy-induced alopecia in women with early breast cancer (protocol) (2025)

Peer-Reviewed Study · Kojima Y, Taruno K, Harada K, et al. (Cochrane Database Syst Rev 2025;8(8):CD016196) · August 1, 2025

Kojima Y et al., 2025-08-01: This is a published protocol, not a completed Cochrane review: it sets out the planned question on scalp cooling for chemotherapy-induced alopecia in early breast cancer. No completed Cochrane review of scalp cooling was located as of 18 November 2026.

To assess the benefits and harms of scalp cooling for the prevention of hair loss from adjuvant or neoadjuvant chemotherapy in women with early breast cancer.

Protocol objectives (abstract)

Kojima Y et al., 2025-08-01: This is a published protocol, not a completed Cochrane review: it sets out the planned question on scalp cooling for chemotherapy-induced alopecia in early breast cancer. No completed Cochrane review of scalp cooling was located as of 18 November 2026. Funder: 'No internal source of support' and 'No external source of support'. Conflicts: authors declare none relevant; HN received research funding and consulting fees from GlaxoSmithKline, Sony and Kowa outside the work. Intervention: scalp cooling devices; makers not named. Comparator: no scalp cooling. Cite as a protocol – any statement that Cochrane has concluded scalp cooling works would be unsupported. PMC12315090.